Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Book profits in pharma: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can book profits in pharma stocks.

    • Buy Glenmark Pharma, says Deepak Shenoy

      Deepak Shenoy, founder of capitalmind.in recommends buying Glenmark Pharma.

    • Here are top 10 stocks to focus on April 8

      Here are top 10 stocks to focus on April 8 - Jubilant Life, Exide, SBI, HDFC Bank, ICICI Bank, Dr Reddys, DLF, HDIL, SKS Micro and Coal India.

    • Buy Dr Reddy's Labs; sell Reliance Infra, Zee Ent: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Dr Reddy's Labs and advises selling Reliance Infrastructure and Zee Entertainment Enterprises.

    • Buy Dr Reddy's Labs, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Dr Reddy‘s Laboratories.

    • Mithil Pradhan bullish on pharma space

      Mithil Pradhan of Violet Arc Global Managers has a bullish stance on pharma space.

    • Prefer Dr Reddy‘s Labs: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking is of the view that one may prefer Dr Reddy‘s Labs.

    • Avoid pharma stocks: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may avoid pharma space.

    • Buy Cipla, says Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Cipla as the stock may move towards Rs 780-775.

    • Go long in Dr Reddy's Labs: Amit Gupta

      Amit Gupta of ICICIdirect is of the view that one can go long in Dr Reddy's Laboratories and feels that Apollo Hospitals Enterprises may hit Rs 1540-1550.

    • Expect 5-6% upside in Cipla, Dr Reddy's: Rahul Mohindar

      Rahul Mohindar of viratechindia.com is of the view that one may see 5-6 percent upside in Cipla and Dr Reddy's Labs.

    • Buy Cipla, Dr Reddy's Labs; sell SBI: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Cipla and Dr Reddy's Labs and advises selling SBI.

    • Here are top 10 stocks to focus on March 17

      Here are top 10 stocks to focus on March 17 - HCL Technologies, Jet Airways, Dr Reddys, Hindustan Unilever (HUL), HDFC Bank, Bank of Baroda, Amtek Auto, Indian Hotel, BHEL and Zee Media.

    • Buy pharma stocks: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying pharma stocks.

    • Prefer pharma stocks: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may prefer pharma stocks.

    • Prefer Dr Reddy's, Lupin, Cipla, Ipca Labs: Anmol Ganjoo

      Anmol Ganjoo of JM Financial Institutional Securities is of the view that one may prefer Dr Reddy's Laboratories, Lupin, Cipla, Ipca Labs and Torrent Pharma.

    • Expect 30-40% upside in Dishman Pharma: Kunal Bothra

      Kunal Bothra of LKP Securities is of the view that one may see 30-40 percent upside in Dishman Pharma.

    • Buy Dr Reddy's Labs, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Dr Reddy's Labs. "One may see momentum on the upside in Dish TV," he adds.

    • Budget impact: Top 20 stocks to buy post FM's proposals

      Here are 20 stocks to buy recommended by Prabhudas Lilladher. Market experts see it to be a well-balanced Budget and expect it to give some legs to the rally on Monday. Ramesh Damani, Member, BSE also agrees that it may not be a big bang Budget but it seems like a big bold Budget.

    • Go long in Dr Reddy's Labs: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking recommends going long in Dr Reddy's Labs on every decline.

    • Sudarshan Sukhani upbeat on Dr Reddy's Laboratories

      Sudarshan Sukhani of s2analytics.com is upbeat on Dr Reddy's Laboratories.

    • Hitesh Mahida cautious on Lupin, prefers Dr Reddy's Labs

      Hitesh Mahida of Antique Stock Broking is cautious on Lupin and feels that one can buy Dr Reddy‘s Laboratories and Glenmark Pharma.

    • Buy Dr Reddy's Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Dr Reddy's Laboratories and is upbeat on IT and pharma space.

    • Accumulate Dr Reddy's Labs on every dip, says Deven Choksey

      Deven Choksey of KR Choksey Shares & Securities recommends accumulating Dr Reddy's Laboratories on every dip and feels that Glenmark Pharma and Cipla holds good potential for an upmove going forward.

    • 'Ranbaxy's Nexium generic loss may up Cipla's EPS 3-5%'

      The US FDA‘s decision to revoke the 180-day exclusivity cover extended to Indian firm Ranbaxy to sell a generic version of the world‘s second-largest selling drug esomeprazole is likely to help rival Cipla, according to Vivek Kumar, research analyst, SBICap Securities.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347